

ANAGENICS

ASX: AN1

Growing a portfolio
of innovative health,
beauty, and
wellness brands

2023 Annual General Meeting



Disclaimer

Forward Looking Statement and Disclosures. This presentation is not making any offer, inducement, solicitation or invitation of any kind by communication of this presentation to the recipient and under no circumstances is it to be construed as, a prospectus or an advertisement.

Without limiting the generality of the foregoing, this presentation is intended to be communicated only to such persons as Anagenics is legally able to send it and who are legally able to receive it in their jurisdiction of residence. If you are not such a person, please return it to Anagenics immediately. Information in this presentation is believed by Anagenics to be fair and accurate but neither Anagenics nor any other person accepts responsibility for such fairness or accuracy. This presentation has not been formally verified. No reliance may, nor should be placed upon the contents of this presentation by any person for any purposes whatsoever. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of any future date and will not be updated or otherwise revised to reflect information that subsequently becomes available, or circumstances existing or changes occurring after the date hereof. Recipients should not construe the contents of this presentation (or any discussions relating to it) as legal, tax, regulatory, financial, investment, accounting or other advice or as


a recommendation by Anagenics or any other person in respect of any matter whatsoever. While Anagenics believes that any projected returns, or other forward-looking statements, included in this presentation relating to pipeline or illustrative investments are based on assumptions and valuation methodologies that are reasonable under the circumstances, the actual realised returns on any such investments will depend on, among other factors, future operating results, the value of the assets and market conditions at the time of disposition, any related transaction costs and the timing and manner of sale, all of which may differ from the assumptions on which the valuations used in this presentation are based. Accordingly, the actual realised return of any such investments mentioned herein may differ materially from the projected returns indicated herein. Historic experience of any persons associated with Anagenics, and past, targeted or projected performance, is not necessarily indicative of future results and there can be no assurance that any targeted or projected returns will be achieved. The information contained herein, unless otherwise indicated, is subject to change and Anagenics assumes no obligation to update the information herein. No representation or warranty, express or implied, is or will be given by Anagenics or any of its directors, members, shareholders, partners, officers, employees, consultants, advisers or agents (together, its "Related Persons"), and, without prejudice to any liability for, or remedy in respect of, fraudulent

misrepresentation, no responsibility or liability or duty of care is, or will be, accepted by Anagenics or any of its Related Persons as to the fairness, accuracy, completeness, currency, reliability or reasonableness of the information or opinions contained in this presentation, or of any other written or oral information made available to any recipient or its advisers in connection with this presentation. Accordingly, none of Anagenics or its Related Persons shall be liable (save in the case of fraud) for any loss (whether direct, indirect or consequential) or damage suffered by any person as a result of relying on any statement in, or omission from, this presentation. This presentation and the rights and obligations of the recipients arising out of or in connection with it are governed by the laws of Australia, and the courts of Australia shall have exclusive jurisdiction to hear and decide any proceedings relating to any claim or dispute arising from or in connection with this presentation.

A premium beauty, health, and wellness company

Our mission is to drive profitable growth through a portfolio of brands and commercialising everyday products.

We achieve this through creating and distributing scientifically validated, innovative consumer products.



Product Brands

IN-HOUSE
évolis, USPA

EXCLUSIVE DISTRIBUTION

HydroPeptide, Priori, Thalgo,
Comfort Zone, Inika & Alpha H

B2B

Distribution and licensing
across Australia and New
Zealand with opportunities
with new distribution
agreements, Inika & Alpha H

B2C

E-commerce platforms
and marketplace
directly servicing
ANZ consumers

A desirable portfolio serving global markets

Underpinned by profitable, trusted, and validated leading brands

\$10m[^]

Total revenue & other income

up 26%*

48%

Gross margin



22 employees

\$2m

eComm sales
(21% of revenue)

[^]FY23 results

*On a continuing operations basis

PARTNERSHIPS



1,110

Accounts across ANZ

8

Brands exclusive distributor

ADDITIONAL VALUE STREAMS

- Lynamid licensing agreement for 35 patents. Royalties payable to Anagenics post commercialisation
- Earn out entitlements from Japan post divestment of Advangan Japan

IP, FORMULAS, AND OWNED TRADEMARKS

- **USPA**
Worldwide trademark and formulations owned
- **Evolis**
Worldwide trademark owned
- 7 patents protecting hair loss treatment with a variety of plant derived monoterpenes
- 7 non-commercialised patents protecting hair loss treatment with midkine protein

TEAM EXPERIENCE

- Samsung
- Boardriders
- Ella Bache
- Alceon Group
- CVC limited
- Alphapharm
- ModelCo
- KPMG

KEY BRANDS

THALGO
LA BEAUTÉ MARINE

USPA

HydroPeptide

[comfort zone]
conscious skin science

PRIORI
ADAPTIVE SKINCARE

INIKA
ORGANIC

évolis

Anagenics has laid the foundations for sustainable profitability

NOVEMBER 2021

APRIL 2023

JUNE 2023

JUNE 2023

AUGUST 2023



bhc.
EST. 1974

INORGANIC

Successful transaction and acquisition of BLC Cosmetics

TALENT

Appointed new CEO Scott Greasley who brings 15 years of building and integrating market-leading profitable businesses both pre and post M&A activity

Underlying EBITDA¹ improved

+43%

FY23 vs FY22


PROACTIVELY SOUGHT TO REDUCE LOSSES VIA COST OUT INITIATIVES

This excludes the loss on disposal of the Advangen Japan \$0.9m



SOUGHT SYNERGIES AND OPERATIONAL EFFICIENCIES

Through consolidation of warehouses and transitioning Advangen LLC to a distributor for Evolis



ACQUISITION OF FACE MEDIGROUP

+50% Pro-Forma revenue

Providing scale to leverage refined cost base

Road to Profitability

| | (\$'000) 2023 ² | (\$'000) 2022 ³ | (\$'000) 2021 | (\$'000) 2020 | (\$'000) 2019 |
|--|-------------------------------|-------------------------------|------------------|------------------|------------------|
| Revenue & Other Income | 9,909 | 10,004 | 6,820 | 8,548 | 8,347 |
| EBITDA – Underlying¹ | (1,661) | (2,899) | (2,715) | (3,739) | (3,590) |
| Loss After Income Tax | (2,667) | (3,649) | (3,387) | (4,907) | (5,910) |
| Earnings Per Share | (1.0) | (1.7) | (2.4) | (5.0) | (7.8) |

¹EBITDA underlying is defined as net profit before interest, tax, depreciation and amortisation, further adjusted by removing foreign exchange/losses and individually material revenue/expenses items that are considered abnormal, non-recurring and typically non-cash in nature. Underlying EBITDA represents the true performance of the business.

²Part-year contribution of BLC profit

³Part-year impact of restructuring



Up 26%

Revenue and other income from continuing operations (excluding Japan) **was up 26% in FY23 to \$9.7M** (FY22: \$7.7M)



\$2.0M

Total eComm sales \$2.0M (2022: \$1.9M), in total up 5%. DTC channel \$0.9M (2022: \$0.7M) – in total up 29%



Key recruitments

Appointment of CEO, Scott Greasley, CFO Matthew Dudek and non-executive director Karen Matthews to round out executive management team

Performance Highlights – FY23



Strong performance

Strong sales performance from key brands despite challenging macroeconomic trading conditions supported by Inika Organic (July 22) and the purchase of USPA (Oct. 22)



Operating costs down 27%

“EBITDA – operating” losses narrowing on prior year (down 27%), improving year on year under revenue and cost savings strategies implemented



+30%

Improvement on operating cash flow vs. FY22. FY23 operating cash (-\$1.8m) vs. FY22 (-\$2.2m)

FY24 initiatives

Anagenics is working to accelerate:

- Streamlining and simplifying platforms
- Profiting from M&A
- Growing Brands



Integrate & onboard
Face MediGroup,
providing scale



Proactively source
M&A opportunities
to find earnings
accretive businesses



Brand Development and
expansion via USPA, Alpha H
and greater engagement with
the hospitality / spa channel



Grow margins by
securing better pricing
and vendor partnerships



Commitment to further
invest in operations to
better service our
customers (IT, D2C, B2B)



Earnings Accretive M&A Opportunities

AN1 is uniquely positioned to move quickly on opportunities that provide the ability to drive further operational efficiencies and build further revenue growth.

AN1 has clarity on
the type of deals
it is seeking and the
team to quickly and
effectively execute.

Accretive targets

Profitable and values-based businesses at the right price

Agility

Ability to move fast for the right deal and be opportunistic.

Ability

Capability to drive further operational efficiencies and build further revenue growth.

ANAGENICS

Unlock growth opportunities with Anagenics

Authorised for release to the ASX by AN1 Board of Directors

Anagenics Limited
Suite 204, Level 2
55 Clarence Street
Sydney, NSW, 2000

info@anagenics.com

anagenics.com

Sandy Beard
Chairman
p: +61 412 308 263

Scott Greasley
CEO & Managing Director
p: +61 473 152 598